Larry Sutton, MD, PhD

home / authors / larry-sutton-md-phd

CEO of Lopoxy Therapeutics and Clinical Scientist.

Articles

Targeting C difficile with Oxygen-Based Therapy

January 13th 2025

Larry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.

Fighting C difficile Before It Starts: Lopoxy Therapeutics Approach

Sophia Abene;Larry Sutton, MD, PhD

January 10th 2025

CEO Larry Sutton, MD, PhD, discusses SIDIPREV, a novel oxygen-based therapy aimed at preventing C difficile infections.

Published: August 27th 2024 | Updated: August 28th 2024

Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties

Published: January 21st 2025 | Updated: January 24th 2025

Rezafungin is Noninferior to Caspofungin For All-Cause Mortality in Treating Candida Infections

Published: January 13th 2025 | Updated: January 24th 2025

Looking at the Slow Adoption of AUC-Based Monitoring for Vancomycin

Published: January 14th 2025 | Updated: January 24th 2025

Estimating the AUC for Vancomycin Using Non Trapezoidal Equations

Published: January 20th 2025 | Updated: January 24th 2025

Debating the Value of Incorporating Antibiotic Stewardship Principles Into Infection Guidelines

Published: January 17th 2025 | Updated: January 24th 2025

Seasonal Respiratory Virus Season: How Are We Doing Right Now?

Do Not Sell My Information

Privacy

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Larry Sutton, MD, PhD

Articles

Latest Updated Articles